ATI LPN
Pharmacology and the Nursing Process 10th Edition Test Bank
Chapter 46 : Antineoplastic Drugs Part 2: Cell Cycle?Nonspecific Drugs and Miscellaneous Drugs Questions
Question 1 of 5
A female patient is receiving palliative therapy with androgen hormones as part of treatment for inoperable breast cancer. The nurse will discuss with the patient which potential body image changes that may occur as adverse effects?
Correct Answer: A
Rationale: Androgens used for cancer treatment, such as fluoxymesterone and testolactone, can cause menstrual irregularities, virilization of female, gynecomastia, hirsutism, acne, anxiety, headache, and nausea. The patient needs to be told of these effects before therapy begins.
Question 2 of 5
During chemotherapy, a patient develops severe diarrhea caused by a vasoactive intestinal peptide-secreting tumor (VIPoma). The nurse expects to administer which drug for this problem?
Correct Answer: C
Rationale: Octreotide (Sandostatin) is used for the management of a cancer-related condition called carcinoid crisis and treatment of the severe diarrhea caused by vasoactive intestinal peptide-secreting tumors.
Question 3 of 5
The nurse is assessing a patient who is receiving chemotherapy with an alkylating drug. Which assessment findings would be considered indications of an oncologic emergency? (Select all that apply.)
Correct Answer: A,D,E
Rationale: Dry, scratchy, or swollen throat, white patches in the mouth or throat, and a temperature of 100.7?°F or higher may indicate an oncologic emergency, such as infection or mucositis, requiring immediate attention. Loss of hair and decreased red blood cell count are common side effects but not emergencies.
Question 4 of 5
When a patient is receiving cisplatin chemotherapy, the nurse will monitor for which adverse effects? (Select all that apply.)
Correct Answer: A,C,D,E
Rationale: Cisplatin can cause nephrotoxicity, ototoxicity, and peripheral neuropathy. Nephrotoxicity is manifested by rising blood urea nitrogen and creatinine levels; ototoxicity is manifested by tinnitus, hearing loss, and dizziness; peripheral neuropathy is manifested by numbness or tingling of the extremities.
Question 5 of 5
A patient will be receiving mitoxantrone, 12 mg/m?²/day every 3 weeks, as part of treatment for prostate cancer. Each dose is mixed into a 50-mL bag of D5W and needs to infuse over 15 minutes. The infusion pump delivers the dose at milliliters per hour. Identify the rate the nurse will set the pump to infuse.
Correct Answer: 200 mL/hr
Rationale: 15 minutes = 0.25 hour. 50 mL:0.25 hour::x mL:1 hour. (50 ?? 1) = (0.25 ?? x); 50 = 0.25x; x = 200 mL/hr.